Related Experiment Video
Updated: Jan 4, 2026
07:29
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
9.7K
Lipoprotein(a) Testing and Emerging Therapies
Perry Mayo-Malasky1, William H Frishman2
1From the Department of Internal Medicine, Brown University, Rhode Island Hospital, Providence, RI.
Cardiology in Review
|November 6, 2019
Summary
Lipoprotein(a) [Lp(a)] is linked to atherosclerotic cardiovascular disease. New therapies targeting Lp(a) production offer hope for improving patient cardiovascular outcomes.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Lipoprotein(a) [Lp(a)] is strongly associated with atherosclerotic cardiovascular disease (ASCVD).
- Despite evidence linking Lp(a) to ASCVD risk, clinical management strategies remain challenging.
- Current therapies lack specificity in targeting Lp(a) production pathways.
Purpose of the Study:
- To review the established association between Lp(a) and ASCVD.
- To explore novel therapeutic strategies for managing Lp(a) levels.
- To investigate the potential of mRNA-targeting therapies for cardiovascular outcomes.
Main Methods:
- Review of observational studies, Mendelian randomization, and genome-wide association studies.
- Analysis of existing medical therapies for Lp(a) reduction.
- Exploration of antisense-oligonucleotide and RNA interference therapies.
Main Results:
- Robust evidence links elevated Lp(a) to increased ASCVD risk.
- Current treatments for reducing Lp(a) do not consistently demonstrate improved cardiovascular outcomes.
- Novel therapies targeting mRNA translation show promise for specific Lp(a) reduction.
Conclusions:
- Lp(a) testing is recommended for high-risk populations to refine cardiovascular risk assessment.
- Targeting Lp(a) production at the mRNA level represents a promising therapeutic avenue.
- Further research is needed to establish the clinical efficacy of novel Lp(a)-lowering therapies on cardiovascular events.
Related Concept Videos
01:26Atherosclerosis III: Management
286
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
286
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
413
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
413
01:27Peripheral Artery Disease III: Interprofessional Care
210
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
210
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
151
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
151